NEW YORK – Synthetic biology company DNA Script said on Tuesday that it has launched an early-access program for its Syntax enzymatic DNA synthesis platform.
Members of the program include the London Biofoundry, an Imperial College London-based facility that provides synthetic DNA for academia and industry, and the Australian Institute for Bioengineering and Nanotechnology's Base facility, an mRNA and DNA manufacturing facility within the University of Queensland.
The program, which the company dubbed the DNA Scriptors Early Access Program, allows customers to access DNA Script's Syntax platform prior to its full commercial launch, including new features and kits.
"Our rapid-response COVID-19 projects already benefited from early access to modified oligos, rapidly produced in house, and we are now looking forward to leveraging biotinylated and longer oligos in our NGS and gene synthesis workflows with our partners," said Marko Storch, head of synthetic biology and automation at London Biofoundry, in a statement.
"DNA Script's Syntax System allows us to quickly synthesize DNA according to our precise requirements, which is critical for the manufacture of mRNA vaccines and therapies," said Base Director Tim Mercer. "Being part of the DNA Scriptors Early Access Program provides access to this leading technology needed to speed the manufacture of mRNA vaccines. This access will enable rapid response to emerging infectious diseases and support the development of personalized vaccines in cancer."
The Syntax system received CE marking last November, paving the way for commercial sales in Europe. Earlier this month, DNA Script inked agreements with several distributors throughout the Asia-Pacific region for its instrument.